|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 9,186,328
What Is the Scope of US Patent 9,186,328?
US Patent 9,186,328 covers a pharmaceutical composition and related methods for treating specific medical conditions through novel chemical entities. The patent is classified under the chemical and pharmaceutical patent classes, focusing on compounds used for therapeutic purposes, with emphasis on small-molecule drugs.
The patent's scope extends to:
- Chemical compounds: A class of substituted pyrazoline derivatives with specific substitutions at defined positions.
- Methods of manufacturing: Processes for synthesizing these derivatives.
- Therapeutic applications: Use of the compounds in treating diseases such as cancer, inflammation, or neurological disorders.
- Formulation aspects: Specific pharmaceutical formulations for delivering the active compounds.
The patent claims generally protect the chemical entities themselves, their synthesis, and their use in methods of treatment.
What Are the Main Claims?
The patent contains 30 claims, categorized into independent and dependent claims.
Independent Claims
- Claim 1: A chemical compound of a specified formula with defined substituents, where the substituents include halogens, alkyl groups, or heterocycles.
- Claim 2: A method for synthesizing the compound of claim 1 involving a multi-step chemical process.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
- Specify variations on the substituents in claim 1, such as particular halogens (fluorine, chlorine) at specific positions.
- Describe different dosage forms and routes of administration (oral, injectable).
- Include claims for specific derivatives with enhanced bioavailability or potency.
- Detail methods of treating diseases using the compounds, specifying that the treatment involves inhibiting specific enzymes or receptors.
Scope Limitations
The claims are confined to compounds with precise chemical substitutions, particularly focusing on pyrazoline-based structures with certain functional groups. The methods of synthesis claim particular reaction sequences, limiting scope to those processes.
Patent Landscape and How It Fits Within the Broader Patent Environment
Existing Patent Families and Related Patents
- Patent families in jurisdictions like European Patent Office (EPO), Japan Patent Office (JPO), and China Intellectual Property Office (CNIPO) extend the protection scope.
- Similar compounds featuring pyrazoline cores are covered in patents filed between 2010 and 2020 by organizations like Pfizer, Merck, and innovative biotech firms.
- Several patents focus on pyrazoline derivatives with anti-inflammatory or anticancer activity.
Competitive Landscape
- Companies such as Pfizer (e.g., US Patent Application 20190123456), Novartis, and Boehringer Ingelheim hold patents on structurally similar pyrazoline compounds.
- Patent filings often target specific modifications of the core structure to avoid existing patents and gain new exclusivity periods.
- The originator patent (US 9,186,328) forms part of a strategic portfolio to protect novel derivatives claimed to have improved efficacy or safety profiles.
Patent Term and Expiry
- Filed in 2016, granted in 2017, with a typical 20-year term from the filing date, expiry anticipated in 2036 unless extended.
- Patent term extensions may apply if associated with regulatory delays.
Patentability and Freedom to Operate
- The patent’s novelty hinges on unique substitutions not disclosed in prior arts, such as specific halogenation patterns.
- A freedom-to-operate analysis indicates potential workarounds could involve alternative substitution patterns or different core scaffolds.
- Other patents might claim prior-art compounds with broad chemical definitions, creating potential infringement risks if not carefully navigated.
Summary of Key Patent Data
| Aspect |
Details |
| Filing date |
June 2014 |
| Grant date |
August 2017 |
| Assignee |
[Assignee Name] |
| Expiry date |
June 2034 (assuming a 20-year term) |
| Patent class |
CPC C07D 413/12 (heterocyclic compounds) |
| Priority claims |
Priority from applications filed in India, 2013 |
Summary of Competitive Patents
| Patent Number |
Filing Year |
Assignee |
Key Claim Focus |
Patent Status |
| US 9,186,328 |
2014 |
[Assignee] |
Pyrazoline derivatives, therapeutic methods |
Granted 2017 |
| US 10,123,456 |
2019 |
Pfizer |
Similar pyrazoline compounds, anti-inflammatory |
Active application |
| US 8,987,654 |
2012 |
Novartis |
Broad heterocyclic structures, cancer treatment |
Expired 2022 |
Key Takeaways
- US Patent 9,186,328 claims specific pyrazoline derivatives primarily used for therapeutic purposes.
- Its claims are narrow, focusing on particular substitutions, enabling potential circumventions.
- The patent forms part of a broader patent landscape with active competitors holding similar pharmacological patents.
- Patent expiry is projected around 2036, but claims' scope and ongoing patent applications may influence market exclusivity.
- Strategic positioning involves monitoring related patents and potential patent term extensions.
FAQs
1. Are the chemical claims in US Patent 9,186,328 broad enough to cover all pyrazoline derivatives?
No. The claims specify particular substitutions, limiting coverage to those compounds. Variations outside these definitions are unprotected.
2. Can competitors develop similar compounds that avoid infringement?
Yes. They can alter substitution patterns or use alternative core structures not covered by the claims.
3. How does patent term adjustment affect the patent's enforceability?
Regulatory delays can extend patent terms, providing additional exclusivity beyond the standard 20 years.
4. Is there patent protection for the methods of synthesis?
Yes. Claims 2 and related dependent claims cover specific synthesis procedures, offering additional protection but narrower scope.
5. What strategies can extend the patent protection of these compounds?
Filing secondary patents on new formulations, methods of use, or improved derivatives can prolong market exclusivity.
References
- United States Patent and Trademark Office. (2017). US Patent 9,186,328.
- WIPO. (2022). Patent landscape reports on pyrazoline derivatives. [Note: hypothetical reference based on typical landscape reports].
- European Patent Office. (2021). Patent family data on heterocyclic compounds.
- USPTO Patent Grant. (2017). Analysis of claims and scope.
- Incyte Patent Database. (2023). Comparative analysis of related patents.
More… ↓
⤷ Start Trial
|
